Equity Profile

CORT

Corcept Therapeutics Incorporated

Health CarePharmaceuticals$12.8B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Corcept Therapeutics Incorporated is a pharmaceutical company focused on developing and commercializing drugs to treat severe metabolic and psychiatric disorders. With a market cap of $9 billion, it plays a significant role in the health care sector, particularly in addressing unmet medical needs through innovative therapies.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and increase sales, which is crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CORT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.94%

Avg Stock Reaction

-0.00%

Last Quarter Recap

In Q1-2026, Corcept reported an EPS of -$0.30, matching analyst expectations. The stock reacted slightly negatively, declining by 0.15% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Corcept's upcoming earnings, given the company's focus on innovative treatments. However, the lack of analyst estimates creates uncertainty.

Bull Case

If Corcept can demonstrate strong revenue growth and positive drug approval news, it could lead to a significant rise in stock value.

Bear Case

Conversely, if the company reports disappointing earnings or delays in drug approvals, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue growth figures can Corcept provide for its key drugs this quarter?

Revenue growth is critical for assessing the company's market performance and future prospects.

Are there any updates on drug approval timelines that could impact future earnings?

Timely drug approvals can significantly affect revenue forecasts and investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating Corcept's potential for revenue growth due to its innovative drug pipeline, which could lead to better-than-expected results this quarter.

Supporting Evidence

The options market is pricing in a 20.58% move, indicating significant expectations for volatility.

Corcept's historical performance shows a mixed reaction pattern, suggesting that the stock may not react as negatively as expected to a miss.

Key Risk

If revenue growth exceeds 15%, it could challenge the current cautious market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on how well Corcept can navigate its growth challenges and capitalize on its drug pipeline.

Bull Confirmed If

A revenue growth rate exceeding 15% would confirm the bull case and indicate strong market demand for Corcept's products.

Bear Confirmed If

If revenue growth is below 5%, it would support the bear case and raise concerns about the company's market position.

Pre-Earnings Positioning

Options Market

Implied Move

±20.58%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened volatility expectations around the earnings report.

Options are pricing ±20.6% while CORT has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

58.0%

Calls (72K)P/C Ratio: 1.21Puts (21K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corcept beats expectations, history suggests the stock could rise by around 1.6%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to muted reactions, with the stock potentially moving sideways as investors digest the results.

Miss

If the company misses expectations, the stock could drop by about 0.6%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on revenue growth for key drugs.
2Any commentary on drug approval timelines.
3Insights into market demand for Corcept's products.
4Management's outlook for the next quarter.
5Responses to analyst questions about competitive pressures.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

KRCAMC

Kilroy Realty Corporation

PreviewView

Jul27

PIIAMC

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and increase sales, which is crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CORT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.94%

Avg Stock Reaction

-0.00%

Last Quarter Recap

In Q1-2026, Corcept reported an EPS of -$0.30, matching analyst expectations. The stock reacted slightly negatively, declining by 0.15% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Corcept's upcoming earnings, given the company's focus on innovative treatments. However, the lack of analyst estimates creates uncertainty.

Bull Case

If Corcept can demonstrate strong revenue growth and positive drug approval news, it could lead to a significant rise in stock value.

Bear Case

Conversely, if the company reports disappointing earnings or delays in drug approvals, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue growth figures can Corcept provide for its key drugs this quarter?

Revenue growth is critical for assessing the company's market performance and future prospects.

Are there any updates on drug approval timelines that could impact future earnings?

Timely drug approvals can significantly affect revenue forecasts and investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating Corcept's potential for revenue growth due to its innovative drug pipeline, which could lead to better-than-expected results this quarter.

Supporting Evidence

The options market is pricing in a 20.58% move, indicating significant expectations for volatility.

Corcept's historical performance shows a mixed reaction pattern, suggesting that the stock may not react as negatively as expected to a miss.

Key Risk

If revenue growth exceeds 15%, it could challenge the current cautious market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on how well Corcept can navigate its growth challenges and capitalize on its drug pipeline.

Bull Confirmed If

A revenue growth rate exceeding 15% would confirm the bull case and indicate strong market demand for Corcept's products.

Bear Confirmed If

If revenue growth is below 5%, it would support the bear case and raise concerns about the company's market position.

Pre-Earnings Positioning

Options Market

Implied Move

±20.58%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened volatility expectations around the earnings report.

Options are pricing ±20.6% while CORT has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

58.0%

Calls (72K)P/C Ratio: 1.21Puts (21K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corcept beats expectations, history suggests the stock could rise by around 1.6%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to muted reactions, with the stock potentially moving sideways as investors digest the results.

Miss

If the company misses expectations, the stock could drop by about 0.6%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on revenue growth for key drugs.
2Any commentary on drug approval timelines.
3Insights into market demand for Corcept's products.
4Management's outlook for the next quarter.
5Responses to analyst questions about competitive pressures.